title: The effects of rapamycin in murine peripheral nerve isografts and allografts.
abstract: The FKBP-12-binding ligand FK506 has been successfully used to stimulate nerve regeneration and prevent the rejection of peripheral nerve allografts. The immunosuppressant rapamycin, another FKBP-12-binding ligand, stimulates axonal regeneration in vitro, but its influence on nerve regeneration in peripheral nerve isografts or allografts has not been studied. Sixty female inbred BALB/cJ mice were randomized into six tibial nerve transplant groups, including three isograft and three allograft (C57BL/6J) groups. Grafts were left untreated (groups I and II), treated with FK506 (groups III and IV), or treated with rapamycin (groups V and VI). Nerve regeneration was quantified in terms of histomorphometry and functional recovery, and immunosuppression was confirmed with mixed lymphocyte reactivity assays. Animals treated with FK506 and rapamycin were immunosuppressed and demonstrated significantly less immune cell proliferation relative to untreated recipient animals. Although every animal demonstrated some functional recovery during the study, animals receiving an untreated peripheral nerve allograft were slowest to recover. Isografts treated with FK506 but not rapamycin demonstrated significantly increased nerve regeneration. Nerve allografts in animals treated with FK506, and to a lesser extent rapamycin, however, both demonstrated significantly more nerve regeneration and increased nerve fiber widths relative to untreated controls. The authors suggest that rapamycin can facilitate regeneration through peripheral nerve allografts, but it is not a neuroregenerative agent in this in vivo model. Nerve regeneration in FK506-treated peripheral nerve isografts and allografts was superior to that found in rapamycin-treated animals. Rapamycin may have a role in the treatment of peripheral nerve allografts when used in combination with other medications, or in the setting of renal failure that often precludes the use of calcineurin inhibitors such as FK506.
authors.affiliation: Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, One Barnes-Jewish Hospital Plaza, East Pavilion, St. Louis, MO 63110, USA.
authors.forename: Terence M
authors.initials: TM
authors.lastname: Myckatyn
authors.forename: Ramsey A
authors.initials: RA
authors.lastname: Ellis
authors.forename: Aaron G
authors.initials: AG
authors.lastname: Grand
authors.forename: Subhro K
authors.initials: SK
authors.lastname: Sen
authors.forename: James B
authors.initials: JB
authors.lastname: Lowe
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hunter
authors.forename: Susan E
authors.initials: SE
authors.lastname: Mackinnon
mesh_terms: D000818:Animals; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008124:Locomotion; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008807:Mice, Inbred BALB C; D009416:Nerve Regeneration / Q000187:drug effects*; D020127:Recovery of Function; D020123:Sirolimus / Q000494:pharmacology*; D016559:Tacrolimus / Q000494:pharmacology*; D013979:Tibial Nerve / Q000166:cytology / Q000637:transplantation*; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus